A novel NF-κB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors

Blood

Volumn 105, Issue 6, 2005, Pages 2324-2331

  Tanaka, Akane ^b   Konno, Masayo ^b   Muto, Susumu ^b   Kambe, Naotomo ^b   Morii, Eiichi ^b   Nakahata, Tatsutoshi ^b   Itai, Akiko ^b   Matsuda, Hiroshi ^a  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D2; CYCLIN D3; CYCLIN E; I KAPPA B; IMATINIB; IMD 0354; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUTANT PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; PROTEIN TYROSINE KINASE INHIBITOR; PYRROLIDINE DITHIOCARBAMATE; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; CYCLINE; N (3,5 BIS(TRIFLUOROMETHYL)PHENYL) 5 CHLORO 2 HYDROXYBENZAMIDE; N-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-5-CHLORO-2-HYDROXYBENZAMIDE;

AMINO ACID SEQUENCE; ARTICLE; AUTOPHOSPHORYLATION; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; DNA BINDING; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MAST CELL; MASTOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE; ACTIVE TRANSPORT; AMINO ACID SUBSTITUTION; BIOSYNTHESIS; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; POINT MUTATION; SYSTEMIC MASTOCYTOSIS; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ACTIVE TRANSPORT, CELL NUCLEUS; AMINO ACID SUBSTITUTION; BENZAMIDES; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CYCLINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; NF-KAPPA B; POINT MUTATION; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-KIT; SIGNAL TRANSDUCTION;

EID: 15244341289     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-08-3247     Document Type: Article

References (47)

1. Kitamura Y, Tsujimura T, Jippo T, et al. Regulation of development, survival and neoplastic growth of mast cells through the c-kit receptor. Int Arch Allergy Immunol. 1995;107:54-56.
2. Kanakura Y, Furitsu T, Tsujimura T, et al. Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line. Leukemia. 1994; (suppl 1):S18-S22.
3. Tsujimura T, Furitsu T, Morimoto M, et al. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. Blood. 1994;83: 2619-2626.
4. Tsujimura T, Furitsu T, Morimoto M, et al. Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3. Int Arch Allergy Immunol. 1995;106:377-385.
5. Kitayama H, Tsujimura T, Matsumura I, et al. Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase. Blood. 1996;88:995-1004.
6. Tsujimura T, Kanakura Y, Kitamura Y. Mechanisms of constitutive activation of c-kit receptor tyrosine kinase. Leukemia. 1997;(suppl 3):396-398.
7. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-580.
8. Brockow K, Metcalfe DD. Mastocytosis. Curr Opin Allergy Clin Immunol. 2001;1:449-454.
9. Sundstrom M, Vliagoftis H, Karlberg P, et al. Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. Immunology. 2003;108:89-97.
10. Vosseller K, Stella G, Yee NS, Besmer P. c-kit receptor signaling through its phosphatidylinositide-3′-kinase-binding site and protein kinase C: role in mast cell enhancement of degranulation, adhesion, and membrane ruffling. Mol Biol Cell. 1997;8:909-922.
11. Linnekin D. Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol. 1999;31:1053-1074.
12. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052-1056.
13. Zermati Y, De Sepulveda P, Feger F, et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene. 2003;22:660-664.
14. Akin C, Fumo G, Yavuz AS, et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood. 2004;103:3222-3225.
15. Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet. 2003;362:535-537.
16. Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway and the restriction point. Curr Opin Cell Biol. 1996;8:805-814.
17. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 2000;60:3689-3695.
18. Ezhevsky SA, Nagahara H, Vocero-Akbani AM, et al. Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb. Proc Natl Acad Sci U S A. 1997;94:10699-10704.
19. Liu DX, Greene LA. Neuronal apoptosis at the G1/S cell cycle checkpoint. Cell Tissue Res. 2001;305:217-228.
20. Keenan SM, Lents NH, Baldassare JJ. Expression of cyclin E renders cyclin D-CDK4 dispensable for inactivation of the retinoblastoma tumor suppressor protein, activation of E2F, and G1-S phase progression. J Biol Chem. 2004;279:5387-5396.
21. Itakura A, Miura Y, Hikasa Y, Kiso Y, Matsuda H. Interleukin-3 and stem cell factor modulate cell cycle regulatory factors in mast cells: negative regulation of p27Kip1 in proliferation of mast cells induced by interleukin-3 but not stem cell factor. Exp Hematol. 2001;29:803-811.
22. Ghosh S, May M, Kopp E. NF-κB and Rel proteins: evolutionary conserved mediators of immune response. Annu Rev Immunol. 1998;16:225-260.
23. Barnes PJ, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066-1071.
24. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest. 2001;107:241-246.
25. Yamamoto Y, Gaynor RG. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Invest. 2001;107:135-142
26. Joyce D, Albanese C, Steer J, et al. NF-κB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev. 2001;12:73-90.
27. Takebayashi T, Higashi H, Sudo H, et al. NF-kappa B-dependent induction of cyclin D1 by retinoblastoma protein (pRB) family proteins and tumor-derived pRB mutants. J Biol Chem. 2003; 278:14897-14905.
28. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol. 2003;171:88-95.
29. Piatelli MJ, Wardle C, Blois J, et al. Phosphatidylinositol 3-kinase-dependent mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 and NF-kappaB signaling pathways are required for B cell antigen receptor-mediated cyclin D2 induction in mature B cells. J Immunol. 2004;172:2753-2762.
30. Tanaka A, Arai K, Kitamura Y, Matsuda H. Matrix metalloproteinase-9 production, a newly identified function of mast cell progenitors, is downregulated by c-kit receptor activation. Blood. 1999;94: 2390-2395.
31. Kitayama H, Kanakura Y, Furitsu T, et al. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood. 1995;85:790-798.
32. Hashimoto K, Tsujimura T, Moriyama Y, et al. Transforming and differentiation-inducing potential of constitutively activated c-kit mutant gene in the IC-2 murine interleukin-3-dependent mast cell line. Am J Pathol. 1996;148:189-200.
33. Kanbe N, Tanaka A, Kanbe M, et al. Human mast cells produce matrix metalloproteinase 9. Eur J Immunol. 1999;29:2645-2649.
34. Delhase M, Hayakawa M, Chen Y, Karin M. Positive and negative regulation of IκB kinase activity through IKKκ subunit phosphorylation. Science. 1999;284:309-313.
35. Brennan P, O'Neill LAJ. 2-Mercaptoethanol restores the ability of nuclear factor κB (NF-κB) to bind DNA in nuclear extracts from interleukin-1-treated cells incubated with pyrrolidine dithiocarbamate (PDTC). Biochem J. 1996;320:975-981.
36. Rosen IB, Musclow CE. DNA histogram of parathyroid tissue in determining extent of parathyroidectomy. Surgery. 1985;98:1024-1030.
37. Ma Y, Zeng S, Metcalfe DD, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 2002;99:1741-1744.
38. Coward WR, Okayama Y, Sagara H, et al. NF-κB and TNF-α: a positive autocrine loop in human lung mast cells? J Immunol. 2002;169:5287-5293.
39. Lorentz A, Klopp I, Gebhardt T, Manns MP, Bischoff SC. Role of activator protein 1, nuclear factor-κB, and nuclear factor of activated T cells in IgE receptor-mediated cytokine expression in mature human mast cells. J Allergy Clin Immunol. 2003;111:1062-1068.
40. Marquardt DL, Walker LL. Dependence of mast cell IgE-mediated cytokine production on nuclear factor-kappaB activity. J Allergy Clin Immunol. 2000;105:500-505.
41. Stassen M, Muller C, Arnold M, et al. IL-9 and IL-13 production by activated mast cells is strongly enhanced in the presence of lipopolysaccharide: NF-kappa B is decisively involved in the expression of IL-9. J Immunol. 2001;166:4391-4398.
42. Takeuchi K, Koike K, Kamijo T, et al. STI571 inhibits growth and adhesion of human mast cells in culture. J Leukoc Biol. 2003;74:1026-1034.
43. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR. The E2F transcription factor is a cellular target for the RB protein. Cell. 1991;65:1053-1061.
44. Keenan SM, Lents NH, Baldassare JJ. Expression of cyclin E renders cyclin D-CDK4 dispensable for inactivation of the retinoblastoma tumor suppressor protein, activation of E2F, and G1-S phase progression. J Biol Chem. 2004;279:5387-5396.
45. Nath N, Wang S, Betts V, Knudsen E, Chellappan S. Apoptotic and mitogenic stimuli inactivate Rb by differential utilization of p38 and cyclin-dependent kinases. Oncogene. 2003;22:5986-5994.
46. Duman-Scheel M, Weng L, Xin S, Du W. Hedgehog regulates cell growth and proliferation by inducing cyclin D and cyclin E. Nature. 2002;417:299-304.
47. Serve H, Yee NS, Stella G, Sepp-Lorenzino L, Tan JC, Besmer P. Differential roles of PI3-kinase and Kit tyrosine 821 in Kit receptor-mediated proliferation, survival and cell adhesion in mast cells. EMBO J. 1995;14:472-483.